Authors

Latest:

Dr. Piccirillo on the Safety Profile of Bevacizumab Plus Erlotinib in EGFR+ Nonsquamous NSCLC

Maria Carmela Piccirillo, MD, discusses the safety profile of bevacizumab plus erlotinib in EGFR-mutated advanced nonsquamous non–small cell lung cancer.

Dana Zakalik, MD

Latest:

Dr Zakalik on the Role of Genetic Testing to Guide Breast Cancer Treatment

Dana Zakalik, MD, discusses the critical role of genetic testing in managing breast cancer.

Marijo Bilusic, MD, PhD

Latest:

Dr Bilusic on the Investigation of Enfortumab Vedotin in Rare GU Cancers

Marijo Bilusic, MD, PhD, discusses the investigation of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors.

Sunnie Kim, MD

Latest:

Dr. Kim on Tislelizumab in Advanced ESCC

Sunnie Kim, MD, contextualizes the use of tislelizumab as a frontline treatment option in advanced esophageal squamous cell carcinoma.

Anurag Singh, MD

Latest:

Dr. Singh on the Potential Effects of Radiation Timing in Head and Neck Cancer

Anurag Singh, MD, discusses the potential effects of radiation timing in head and neck cancer.

Janaki Neela Sharma, MD

Latest:

Dr Sharma on the Role of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Janaki Neela Sharma, MD, discusses how data from EV-302 further defined the role of frontline enfortumab vedotin plus pembrolizumab in bladder cancer.

Aakash Desai, MBBS, MPH

Latest:

Dr Desai on Unmet Needs With Chemoimmunotherapy in NSCLC

akash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer.

Mary Redman, PhD

Latest:

Designing Trials and Fueling Collaboration in Oncology: With D. Ross Camidge, MD, PhD; and Mary Redman, PhD

Drs Camidge and Redman discuss Dr Redman's role as a biostatistician at Fred Hutch, outlining her work in designing clinical trials.

Saad J. Kenderian, MB, CHB

Latest:

Dr Kenderian on the Efficacy of Liso-Cel in R/R CLL/SLL

Saad J. Kenderian, MB, CHB, consultant, discusses the safety and efficacy findings derived from the phase 1/2 TRANSCEND CLL 004 study in CLL/SLL.

Yi-Long Wu, MD, PhD

Latest:

Dr Wu on SAFFRON-301 Data in Advanced or Metastatic NSCLC

Yi-Long Wu, MD, PhD, discusses findings from the phase 3 SAFFRON-301 trial in patients with advanced or metastatic NSCLC.

American Society for Clinical Pathology

Latest:

ASCP’s Outstanding Education Initiatives Receive Prestigious Awards

Two innovative ASCP education initiatives have received accolades from the Alliance for Continuing Education in the Health Professions.

Adam E. Singer, MD, PhD

Latest:

Dr Singer on Choosing Between Frontline IO/IO and IO/TKI Regimens in RCC

Adam E. Singer, MD, PhD, discusses factors that inform the choice between IO/IO and IO/TKI regimens for patients with renal cell carcinoma.

Novartis Sponsored Content; OncLive Article with Dr. Erika Hamilton

Latest:

Managing Unseen Risks: Understanding Recurrence in Early Breast Cancer With No or Limited Nodal Involvement

Sarwish Rafiq, PhD

Latest:

Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors

Sarwish Rafiq, PhD, discusses how engineering metabolically fit, memory rich CAR T-cells may address barriers to CAR T-cell efficacy in solid tumors.

Abhishek Tripathi, MD

Latest:

Dr Tripathi on the NEMIO Trial of Durvalumab Plus Chemo With/Without Tremelimumab in MIBC

Abhishek Tripathi, MD, discusses the phase 1/2 NEMIO trial of durvalumab/chemotherapy with/without tremelimumab in muscle-invasive bladder cancer.

Dr. Calvin Chao, Sr. Vice President of Medical Affairs at Tempus

Latest:

A Conversation about Somatic, Incidental Germline, and Standalone Germline Testing in Clinical Practice